Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

被引:4
|
作者
Hsu, Wei-Fan [1 ,2 ,3 ,9 ]
Chang, Kai-Chih [1 ]
Chen, Te-Hong [4 ,9 ]
Lin, Chien-Hung [5 ,9 ]
Lin, Ying-Chun [6 ,9 ]
Tsai, Ming-Hung [7 ,9 ]
Chen, Pei-Yu [8 ,9 ]
Wang, Hung-Wei [1 ,3 ,9 ]
Chu, Chia-Sheng [1 ,9 ]
Peng, Cheng-Yuan [1 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Der Yuh Rd, Taichung 40447, Taiwan
[2] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[3] China Med Univ, Sch Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
[5] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[7] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan
[8] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
[9] China Med Univ Hosp, Liver Canc Team, Taichung, Taiwan
关键词
albumin-bilirubin (ALBI) grade; intermediate-stage hepatocellular carcinoma; Lok grade; noninvasive model; SIGNIFICANT FIBROSIS; LIVER-FUNCTION; HEPATITIS-B; CIRRHOSIS; INDEX; ALBI; SUBCLASSIFICATION; CRITERIA; PROPOSAL; DISEASE;
D O I
10.1097/MD.0000000000027000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models' OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55-72). Most patients had tumor volume <= 50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0-8.5) cm. The median alpha-fetoprotein was 36.25 (6.13-552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77-48.27) months. Across the 10 models, the albumin-bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595-0.693) in all patients. In subgroup analyses, the Lok index, platelet-albumin-bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] THE COMPARISON BETWEEN OVERALL SURVIVAL OF TRANSARTERIAL CHEMOEMBOLIZATION AND BEST SUPPORTIVE CARE IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
    Akarapatima, Keerati
    Chang, Arunchai
    Prateepchaiboon, Tanaporn
    Pungpipattrakul, Nuttanit
    Songjamrat, Apiradee
    Pakdeejit, Songklod
    Rattanasupar, Attapon
    GUT, 2021, 70 : A73 - A74
  • [2] Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma
    Chu, Hee Ho
    Kim, Jin Hyoung
    Shim, Ju Hyun
    Gwon, Dong Il
    Ko, Heung-Kyu
    Shin, Ji Hoon
    Ko, Gi-Young
    Yoon, Hyun-Ki
    Kim, Nayoung
    CANCERS, 2021, 13 (11)
  • [3] Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
    Shimose, Shigeo
    Iwamoto, Hideki
    Tanaka, Masatoshi
    Niizeki, Takashi
    Shirono, Tomotake
    Kajiwara, Akira
    Noda, Yu
    Kamachi, Naoki
    Okamura, Shusuke
    Nakano, Masahito
    Kuromatsu, Ryoko
    Kawaguchi, Takumi
    Koga, Hironori
    Torimura, Takuji
    ONCOLOGY, 2021, 99 (12) : 756 - 765
  • [4] Treatment of intermediate-stage hepatocellular carcinoma
    Alejandro Forner
    Marine Gilabert
    Jordi Bruix
    Jean-Luc Raoul
    Nature Reviews Clinical Oncology, 2014, 11 : 525 - 535
  • [5] Treatment of intermediate-stage hepatocellular carcinoma
    Fomer, Alejandro
    Gilabert, Marine
    Bruix, Jordi
    Raoul, Jean-Luc
    NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (09) : 525 - 535
  • [6] Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Finn, Richard S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 501 - 503
  • [7] Prognostic Score predicting overall survival of Patients with Intermediate Stage of Hepatocellular Carcinoma after Transarterial Chemoembolization
    Jarupongprapa, Saharat
    Nimanong, Supot
    Chainuvati, Siwaporn
    Charatcharoenwitthaya, Phunchai
    Tanwandee, Tawesak
    Chotiyaputta, Watcharasak
    HEPATOLOGY, 2015, 62 : 444A - 445A
  • [8] Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
    Yuichi Sugino
    Koichiro Yamakado
    Takashi Yamanaka
    Masashi Fujimori
    Atsuhiro Nakatsuka
    Haruyuki Takaki
    Yoshiyuki Takei
    Hajime Sakuma
    Shuji Isaji
    Japanese Journal of Radiology, 2017, 35 : 254 - 261
  • [9] Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
    Sugino, Yuichi
    Yamakado, Koichiro
    Yamanaka, Takashi
    Fujimori, Masashi
    Nakatsuka, Atsuhiro
    Takaki, Haruyuki
    Takei, Yoshiyuki
    Sakuma, Hajime
    Isaji, Shuji
    JAPANESE JOURNAL OF RADIOLOGY, 2017, 35 (05) : 254 - 261
  • [10] Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma
    Giannini, Edoardo G.
    Moscatelli, Alessandro
    Pellegatta, Gaia
    Vitale, Alessandro
    Farinati, Fabio
    Ciccarese, Francesca
    Piscaglia, Fabio
    Rapaccini, Gian Lodovico
    Di Marco, Maria
    Caturelli, Eugenio
    Zoli, Marco
    Borzio, Franco
    Cabibbo, Giuseppe
    Felder, Martina
    Sacco, Rodolfo
    Morisco, Filomena
    Missale, Gabriele
    Foschi, Francesco Giuseppe
    Gasbarrini, Antonio
    Baroni, Gianluca Svegliati
    Virdone, Roberto
    Masotto, Alberto
    Trevisani, Franco
    Grp, Italian Liver Canc I. T. A. L. I. C. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (01): : 70 - 77